REPORTS

Let’s Pullulate and Expand Your Business

Neurodegenerative Diseases Drug Market - Global Professional Analysis and Forecast to 2026

Oct 15, 2019  |  163 PAGES  |  REPORT CODE: CMM211385
  • REPORT SUMMARY
  • TABLE OF CONTENTS
  • INDUSTRY COVERAGE

The worldwide Neurodegenerative Diseases Drug market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 5.1% during the forecast period.

This report presents the market size and development trends by detailing the Neurodegenerative Diseases Drug market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Neurodegenerative Diseases Drug market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Neurodegenerative Diseases Drug industry and will help you to build a panoramic view of the industrial development.

Neurodegenerative Diseases Drug Market, By Type:

  • Type 1

  • Type 2

  • Type 3

Neurodegenerative Diseases Drug Market, By Application:

  • End-Users 1

  • End-Users 2

  • End-Users 3

Some of the leading players are as follows:

  • Asubio Pharmaceutical

  • Biogen Idec

  • Amarin

  • Eisai

  • Addex Pharmaceutical

  • UCB

  • H.Lundbeck A/S

  • Alector

  • Bayer Schering Pharma AG

  • Jiangsu Hansoh Pharmaceutical

  • Teva Pharmaceutical

  • Merck Serono

  • Bial

  • Yumanity Therapeutics

  • Yangtze River Pharmaceutical Group

  • Novartis

  • AstraZeneca

  • Pfizer

  • Chongqing Zein Pharmaceutical

  • Boehringer Ingelheim

Geographically, Major regions are analyzed in details are as follows:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Table of Contents

1 Methodology and Scope

  • 1.1 Market Segmentation & Scope

    • 1.1.1 Technology Type

    • 1.1.2 Product

    • 1.1.3 Application

    • 1.1.4 Regional scope

    • 1.1.5 Estimates and forecast timeline

  • 1.2 Research Methodology

  • 1.3 Information Procurement

    • 1.3.1 Purchased database

    • 1.3.2 Internal database

    • 1.3.3 Secondary sources

    • 1.3.4 Primary research

    • 1.3.5 Details of primary research

  • 1.4 Information or Data Analysis

    • 1.4.1 Data analysis models

  • 1.5 Market Formulation & Validation

  • 1.6 Model Details

    • 1.6.1 Commodity flow analysis

    • 1.6.2 Volume price analysis

  • 1.7 List of Secondary Sources

  • 1.8 List of Abbreviations

2 Executive Summary

  • 2.1 Market Outlook

  • 2.2 Segment Outlook

3 Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook

  • 3.1.1 Parent market outlook

    • 3.1.2 Ancillary market outlook

  • 3.2 Market Segmentation

    • 3.2.1 Analysis

  • 3.3 Market Dynamics

    • 3.3.1 Market driver analysis

    • 3.3.2 Market restraint analysis

    • 3.3.3 Industry opportunities

  • 3.4 Penetration & Growth Prospect Mapping

    • 3.4.1 Penetration & growth prospect mapping analysis

  • 3.5 Business Environment Analysis Tools

    • 3.5.1 Porter's five forces analysis

    • 3.5.2 PESTLE analysis

    • 3.5.3 Major deals & strategic alliances analysis

4 Neurodegenerative Diseases Drug Market: Technology Type Analysis

  • 4.1 Neurodegenerative Diseases Drug Technology Type Market Share Analysis, 2018 & 2026

  • 4.2 Neurodegenerative Diseases Drug Technology Type Market: Segment Dashboard

  • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

    • 4.3.1 Type 1

    • 4.3.2 Type 2

    • 4.3.3 Type 3

5 Neurodegenerative Diseases Drug Market: Product Analysis

  • 5.1 Neurodegenerative Diseases Drug Product Market Share Analysis, 2018 & 2026

  • 5.2 Neurodegenerative Diseases Drug Product Market: Segment Dashboard

  • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

6 Neurodegenerative Diseases Drug Market: Application Analysis

  • 6.1 Neurodegenerative Diseases Drug Application Market Share Analysis, 2018 & 2026

  • 6.2 Neurodegenerative Diseases Drug Application Market: Segment Dashboard

  • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

    • 6.3.1 End-User 1

    • 6.3.2 End-User 1

    • 6.3.3 End-User 3

7 Neurodegenerative Diseases Drug Market: Regional Analysis

  • 7.1 Neurodegenerative Diseases Drug Regional Market Share Analysis, 2018 & 2026

  • 7.2 Neurodegenerative Diseases Drug Regional Market: Segment Dashboard

  • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

  • 7.4 List of Players at Regional Level

    • 7.4.1 North America

    • 7.4.2 Europe

    • 7.4.3 Asia Pacific

  • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

    • 7.5.1 North America

    • 7.5.2 Europe

    • 7.5.3 Asia Pacific

    • 7.5.4 Latin America

    • 7.5.5 MEA

  • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

    • 7.6.1 North America

    • 7.6.2 Europe

    • 7.6.3 Asia Pacific

    • 7.6.4 Latin America

    • 7.6.5 Middle East & Africa

8 Competitive Analysis

  • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

  • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

  • 8.3 Vendor Landscape

    • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

9 Company Profiles

  • 9.1 Asubio Pharmaceutical

    • 9.1.1 Asubio Pharmaceutical Company overview

    • 9.1.2 Financial performance

    • 9.1.3 Product benchmarking

    • 9.1.4 Strategic initiatives

    • 9.1.5 SWOT analysis

  • 9.2 Biogen Idec

    • 9.2.1 Biogen Idec Company overview

    • 9.2.2 Financial performance

    • 9.2.3 Product benchmarking

    • 9.2.4 Strategic initiatives

    • 9.2.5 SWOT analysis

  • 9.3 Amarin

    • 9.3.1 Amarin Company overview

    • 9.3.2 Financial performance

    • 9.3.3 Product benchmarking

    • 9.3.4 Strategic initiatives

    • 9.3.5 SWOT analysis

  • 9.4 Eisai

    • 9.4.1 Eisai Company overview

    • 9.4.2 Financial performance

    • 9.4.3 Product benchmarking

    • 9.4.4 Strategic initiatives

    • 9.4.5 SWOT analysis

  • 9.5 Addex Pharmaceutical

    • 9.5.1 Addex Pharmaceutical Company overview

    • 9.5.2 Financial performance

    • 9.5.3 Product benchmarking

    • 9.5.4 Strategic initiatives

    • 9.5.5 SWOT analysis

  • 9.6 UCB

    • 9.6.1 UCB Company overview

    • 9.6.2 Financial performance

    • 9.6.3 Product benchmarking

    • 9.6.4 Strategic initiatives

    • 9.6.5 SWOT analysis

  • 9.7 H.Lundbeck A/S

    • 9.7.1 H.Lundbeck A/S Company overview

    • 9.7.2 Financial performance

    • 9.7.3 Product benchmarking

    • 9.7.4 Strategic initiatives

    • 9.7.5 SWOT analysis

  • 9.8 Alector

    • 9.8.1 Alector Company overview

    • 9.8.2 Financial performance

    • 9.8.3 Product benchmarking

    • 9.8.4 Strategic initiatives

    • 9.8.5 SWOT analysis

  • 9.9 Bayer Schering Pharma AG

    • 9.9.1 Bayer Schering Pharma AG Company overview

    • 9.9.2 Financial performance

    • 9.9.3 Product benchmarking

    • 9.9.4 Strategic initiatives

    • 9.9.5 SWOT analysis

  • 9.10 Jiangsu Hansoh Pharmaceutical

    • 9.10.1 Jiangsu Hansoh Pharmaceutical Company overview

    • 9.10.2 Financial performance

    • 9.10.3 Product benchmarking

    • 9.10.4 Strategic initiatives

    • 9.10.5 SWOT analysis

  • 9.11 Teva Pharmaceutical

    • 9.11.1 Teva Pharmaceutical Company overview

    • 9.11.2 Financial performance

    • 9.11.3 Product benchmarking

    • 9.11.4 Strategic initiatives

    • 9.11.5 SWOT analysis

  • 9.12 Merck Serono

    • 9.12.1 Merck Serono Company overview

    • 9.12.2 Financial performance

    • 9.12.3 Product benchmarking

    • 9.12.4 Strategic initiatives

    • 9.12.5 SWOT analysis

  • 9.13 Bial

    • 9.13.1 Bial Company overview

    • 9.13.2 Financial performance

    • 9.13.3 Product benchmarking

    • 9.13.4 Strategic initiatives

    • 9.13.5 SWOT analysis

  • 9.14 Yumanity Therapeutics

    • 9.14.1 Yumanity Therapeutics Company overview

    • 9.14.2 Financial performance

    • 9.14.3 Product benchmarking

    • 9.14.4 Strategic initiatives

    • 9.14.5 SWOT analysis

  • 9.15 Yangtze River Pharmaceutical Group

    • 9.15.1 Yangtze River Pharmaceutical Group Company overview

    • 9.15.2 Financial performance

    • 9.15.3 Product benchmarking

    • 9.15.4 Strategic initiatives

    • 9.15.5 SWOT analysis

  • 9.16 Novartis

    • 9.16.1 Novartis Company overview

    • 9.16.2 Financial performance

    • 9.16.3 Product benchmarking

    • 9.16.4 Strategic initiatives

    • 9.16.5 SWOT analysis

  • 9.17 AstraZeneca

    • 9.17.1 AstraZeneca Company overview

    • 9.17.2 Financial performance

    • 9.17.3 Product benchmarking

    • 9.17.4 Strategic initiatives

    • 9.17.5 SWOT analysis

  • 9.18 Pfizer

    • 9.18.1 Pfizer Company overview

    • 9.18.2 Financial performance

    • 9.18.3 Product benchmarking

    • 9.18.4 Strategic initiatives

    • 9.18.5 SWOT analysis

  • 9.19 Chongqing Zein Pharmaceutical

    • 9.19.1 Chongqing Zein Pharmaceutical Company overview

    • 9.19.2 Financial performance

    • 9.19.3 Product benchmarking

    • 9.19.4 Strategic initiatives

    • 9.19.5 SWOT analysis

  • 9.20 Boehringer Ingelheim

    • 9.20.1 Boehringer Ingelheim Company overview

    • 9.20.2 Financial performance

    • 9.20.3 Product benchmarking

    • 9.20.4 Strategic initiatives

    • 9.20.5 SWOT analysis

 

The List of Tables and Figures (Totals 92 Figures and 164 Tables)

  • Figure Type 1 Neurodegenerative Diseases Drug market, 2015 - 2026 (USD Million)

  • Figure Type 2 Neurodegenerative Diseases Drug market, 2015 - 2026 (USD Million)

  • Figure Type 3 Neurodegenerative Diseases Drug market, 2015 - 2026 (USD Million)

  • Figure End-Users 1 market, 2015 - 2026 (USD Million)

  • Figure End-Users 2 market, 2015 - 2026 (USD Million)

  • Figure End-Users 3 market, 2015 - 2026 (USD Million)

  • Table List of players in North America

  • Table List of players in Europe

  • Table List of players in Asia Pacific

  • Table SWOT analysis

  • Table North America Neurodegenerative Diseases Drug market, by country, 2015 - 2026 (USD Million)

  • Table North America Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table North America Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table North America Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.S. Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.S. Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.S. Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Canada Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Canada Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Canada Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Europe Neurodegenerative Diseases Drug market, by country, 2015 - 2026 (USD Million)

  • Table Europe Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Europe Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Europe Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table U.K. Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table U.K. Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table U.K. Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Germany Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Germany Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Germany Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table France Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table France Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table France Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Italy Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Italy Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Italy Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Spain Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Spain Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Spain Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neurodegenerative Diseases Drug market, by country, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Asia Pacific Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table China Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table China Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table China Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Japan Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Japan Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Japan Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table India Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table India Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table India Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Latin America Neurodegenerative Diseases Drug market, by country, 2015 - 2026 (USD Million)

  • Table Latin America Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Latin America Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Latin America Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Brazil Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Brazil Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Brazil Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Mexico Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Mexico Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Mexico Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Argentina Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Argentina Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Argentina Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table MEA Neurodegenerative Diseases Drug market, by country, 2015 - 2026 (USD Million)

  • Table MEA Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table MEA Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table MEA Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table South Africa Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table South Africa Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table South Africa Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Regulatory scenario

  • Table Nigeria Neurodegenerative Diseases Drug market, by type, 2015 - 2026 (USD Million)

  • Table Nigeria Neurodegenerative Diseases Drug market, by product, 2015 - 2026 (USD Million)

  • Table Nigeria Neurodegenerative Diseases Drug market, by application, 2015 - 2026 (USD Million)

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Recent Developments & Impact Analysis, by Key Market Participants

  • Table Company market position analysis

  • Table Company Profiles

  • Table Asubio Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Biogen Idec Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Amarin Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Eisai Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Addex Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table UCB Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table H.Lundbeck A/S Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Alector Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bayer Schering Pharma AG Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Jiangsu Hansoh Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Teva Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Merck Serono Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Bial Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Yumanity Therapeutics Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Yangtze River Pharmaceutical Group Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Novartis Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table AstraZeneca Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Pfizer Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Chongqing Zein Pharmaceutical Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

  • Table Company Profiles

  • Table Boehringer Ingelheim Production, Value, Price, Gross Margin 2014-2019

  • Table Product benchmarking

  • Table Strategic initiatives

  • Table SWOT analysis

Report Purchase

reports
$4840
$9680
BUY NOWClick MeBUY NOW
top